Get the Stockscreener App
4.03
4.28%
-0.18
After Hours:
4.10
0.07
+1.74%
Alterity Therapeutics Ltd Adr stock is traded at $4.03, with a volume of 28,844.
It is down -4.28% in the last 24 hours and down -5.18% over the past month.
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
See More
Previous Close:
$4.21
Open:
$4.13
24h Volume:
28,844
Relative Volume:
0.32
Market Cap:
$61.85M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-5.6825
EPS:
-0.7092
Net Cash Flow:
-
1W Performance:
-10.58%
1M Performance:
-5.18%
6M Performance:
+17.15%
1Y Performance:
+244.44%
1-Day Range:
$4.0105
$4.13
1-Week Range:
$4.0105
$4.8545
52-Week Range:
$1.001
$7.00
Alterity Therapeutics Ltd Adr Stock (ATHE) Company Profile
Name
Alterity Therapeutics Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare ATHE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATHE
Alterity Therapeutics Ltd Adr
|
4.03 | 76.31M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Alterity Therapeutics Ltd Adr Stock (ATHE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-03-25 | Downgrade | The Benchmark Company | Speculative Buy → Hold |
| Dec-12-24 | Initiated | Maxim Group | Buy |
Alterity Therapeutics Ltd Adr Stock (ATHE) Latest News
ASX Stock Market News | Australian Shares - new.smallcaps.com.au
Antalpha Platform Holding Company (NASDAQ:ANTA) Short Interest Update - Defense World
Contrasting Alterity Therapeutics (NASDAQ:ATHE) & BioHarvest Sciences (NASDAQ:BHST) - Defense World
CapEx per share of Alterity Therapeutics Ltd. Sponsored ADR – NASDAQ:ATHE - TradingView
Alterity Therapeutics stock rises after positive MSA trial data presented at conference - Investing.com
Alterity Therapeutics (NASDAQ:ATHE) Shares Down 0.5% – What’s Next? - Defense World
Alterity Therapeutics presents ATH434-201 Phase 2 data - TipRanks
ASX recovers to shed just 0.13pc as healthcare and gold drags - Geelong Advertiser
Alterity Therapeutics raises A$20M in strategic placement - MSN
ATHE: A Tale of Ups & Downs – 63.16% gain in 6 Months, 42.35% in 30 Days - investchronicle.com
SMCI’s Market Flip-Flop: Exploring the Volatility of 2025 Performance - investchronicle.com
Alterity CEO to provide corporate update on ATH434 development - Investing.com
Alterity Therapeutics highlighted at MSA Congress - Investing.com
Alterity Therapeutics highlighted at MSA Congress By Investing.com - Investing.com India
Alterity Therapeutics reports Phase 2 data at MSA Congress - Investing.com
Alterity Therapeutics reports Phase 2 data at MSA Congress By Investing.com - Investing.com South Africa
Alterity shares new phase 2 data on MSA treatment - Investing.com India
Alterity Therapeutics announces regulatory notice - Investing.com
Alterity Therapeutics announces compliance notice - Investing.com
Alterity secures funding to advance MSA drug development - Investing.com
Alterity Therapeutics announces trading halt - Investing.com
Alterity Therapeutics reports compliance with Takeovers Panel - Investing.com
Alterity Therapeutics announces securities notice - Investing.com
Alterity Therapeutics reports quarterly activities - Investing.com
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Most active stocks: US stocks with the highest trading volume today - Yahoo
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns - Stockhead
symbol__ Stock Quote Price and Forecast - CNN
Appendix 4E & Annual Report 2023SEC.gov - SEC.gov
Biotech Stocks: Longevity Company Stocks - Investing.com
Alterity Therapeutics LtdADR (ATHE) News, Articles, Events & Latest Updates - Stocktwits
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology - Investing.com India
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire
Ernexa Therapeutics (ERNA) Short Interest Ratio and Volume 2025 - MarketBeat
Trading Halts Explained - MarketBeat
Biggest Stock LosersToday’s Biggest Percentage Decliners - MarketBeat
Genprex (GNPX) Short Interest Ratio and Volume 2025 - MarketBeat
Integrated BioPharma (INBP) Short Interest Ratio and Volume 2025 - MarketBeat
ESSA Pharma (EPIX) Short Interest Ratio and Volume 2025 - MarketBeat
ATHEAlterity Therapeutics Ltd Latest Stock News & Market Updates - Stock Titan
ATH Stock Price and Chart — ASX:ATH - TradingView
ATHE Stock Price and Chart — NASDAQ:ATHE - TradingView
Most Volatile Stocks, What Investors Need to Know - MarketBeat
How Investors Can Identify and Successfully Trade Gap-Down Stocks - MarketBeat
What Investors Need to Know to Beat the Market - MarketBeat
Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time - MarketBeat
Alterity Therapeutics Ltd Adr Stock (ATHE) Financials Data
There is no financial data for Alterity Therapeutics Ltd Adr (ATHE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):